Lowest Price Guaranteed
Pages
1048
Last Updated
January 2026
View Count
32151
The global T-cell therapy market, valued at USD 6.5 billion in 2025, is projected to grow to USD 8.1 billion in 2026 and USD 20.9 billion by 2035, representing a CAGR of 11.2% during the forecast period 2026 to 2035.
To learn more about this report, request a free sample copy
The new research study consists of industry trends, detailed market analysis, clinical trial analysis, key opinion leaders analysis, partnerships and collaborations analysis, funding and investment trends and patent analysis; the report also includes market forecast and opportunity analysis. Driven by the availability of innovative technology platforms, lucrative funding opportunities and encouraging clinical trial results, the T-cell therapy market is poised to grow in the long-run, as multiple product candidates are expected to receive marketing approval in the coming decade.
T cells, a subtype of white blood cells, play a central role as a part of the human body’s immune system. These cells coordinate the bodily responses to foreign allergens and pathogens by effectively recognizing, targeting and destroying them, while remembering the initial encounters for initiating a quick and effective immune response. Since the 19th century, scientists have been actively studying these cells for their potential in the treatment of a myriad of disease indications. In recent years, cell therapies have garnered significant attention for the treatment of difficult to treat diseases, particularly cancer, autoimmune disorders and rare genetic disorders, ultimately decreasing the global disease burden.
 |
 |
 |
Tap or click on the images for smart insights on T-Cell Therapy Market
In this context, T-cell therapy has emerged as a viable immunotherapy, using patients’ own immune cells to identify and attack cancer cells in the body. According to NIH, in 2024, around 2 million people are estimated to be diagnosed with various types of cancer in the U.S. alone and this number is expected to rise in the future at the global level which is likely to spike the T-cell therapy market growth.
Specifically, the increasing number of Acute Lymphoblastic Leukemia cases in young and adults is expected to boost the demand for these therapies. It is worth noting that, in 2024, the US Food and Drug Administration approved multiple T cell therapies targeting cancer (in reverse chronological order), such as Obecabtagene autoleucel / Aucatzyl (relapsed or refractory B-cell precursor acute lymphoblastic leukemia, November 2024), Afamitresgene autoleucel / TECELRA (metastatic or unresectable synovial sarcoma, August 2024) and Lifileucel / Amtagvi (unresectable or metastatic melanoma, February 2024).
Given the significant potential of T-cell therapies, surge in demand for personalized cancer treatment, coupled with the expedited regulatory approvals, the T-cell therapy market is anticipated to rise exponentially over this forecast period. In addition, as the field of immunotherapy continues to evolve, the market is expected to witness a surge in partnership activity, among the leading industry players and academic institutes, primarily for the development and commercialization of innovative T-cell therapies.
 |
 |
 |
Tap or click on the images for smart insights on T-Cell Therapy Market
Although the high initial investment and high cost of therapy may confine the market growth, yet, the combined expertise and resources of multiple stakeholders is expected to help them navigate the complex regulatory landscape and bring these life-saving therapies to patients more efficiently.
The T-cell therapy market report presents an in-depth analysis of various T-cell therapies and companies in this domain, across different segments, as defined in the table below:
| Key Report Attributes | Details | |
| Historical Trend | Since 2018 | |
| Forecast Period | Till 2035 | |
| Current Market Size | $8.1 Billion | |
| Market Size 2035 | $20.9 Billion | |
| CAGR till 2035 | 11.2% | |
| Type of Therapy |
|
|
| Target Indication |
|
|
| Target Antigen |
|
|
| Company Size |
|
|
| Geographical Regions |
|
|
| Key Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
|
|
 |
 |
 |
Tap or click on the images for smart insights on T-Cell Therapy Market
One of the key objectives of this market report was to estimate the current market size, opportunity, and future growth potential of the T-Cell therapy market, over the forecast period. Based on multiple parameters, likely adoption trends, and through primary validations, we have provided an informed estimate of the market evolution during the forecast period till 2035.
The market report also features the likely distribution of the current and forecasted opportunity within the market across various segments, such as type of therapy (CAR-T, TCR and TIL), target indication (multiple myeloma, large B-cell lymphoma, acute lymphoblastic leukemia, diffuse large b-cell lymphoma, diffuse large b-cell lymphoma, primary mediastinal large B-Cell lymphoma, transformed follicular lymphoma and high grade B-cell lymphoma, acute lymphoblastic leukemia / B-cell Non-Hodgkin lymphoma, Non-Hodgkin lymphoma, mantle cell lymphoma, acute myeloid leukemia, generalized myasthenia gravis (MG), renal transplantation (HLA-A2), gastric adenocarcinoma, ovarian / endometrial cancer, chronic lymphocytic leukemia, follicular lymphoma, renal cell carcinoma, melanoma, basal cell carcinoma, lung cancer, sarcoma, head and neck cancer, cervical cancer, neuro gastro-intestinal (GI) Cancer, breast cancer, hepatocellular carcinoma, nasopharyngeal carcinoma and ovarian cancer), target antigen (BCMA, CD19, CD20, CD19 and CD22, HLA, MAGE, PRAME, NY-ESO-1 and LAGE, EBV, HBV and others), company size (small, mid-sized, large, and very large), geographical regions (North America, Europe and Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World), leading players and sales forecast of therapies.
In order to account for future uncertainties and to add robustness to our model, we have provided three T-cell therapy market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in the T-cell therapy market report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following individuals:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD unless otherwise specified.
Based on the type of therapy, the T-cell therapy market is segmented into CAR-T, TCR and TIL therapies. Currently, CAR T-cell therapy market segment captures majority (91%) of the overall market share, reflective of the revenue generated by 11 approved and nine late stage (Phase I / II and above) CAR-T therapies in the market. This can be attributed to the fact that CAR-T therapy is a controlled, precise and short span treatment approach, that has demonstrated durable cancer remission rates.
However, TIL therapy market segment is anticipated to grow at a relatively faster pace, owing to their versatility in targeting a wide range of cancerous indications and encouraging clinical trial results.
Based on the target indication, the T-cell therapy market is segmented into multiple myeloma, large B-cell lymphoma, acute lymphoblastic leukemia, diffuse large b-cell lymphoma, diffuse large b-cell lymphoma, primary mediastinal large B-Cell lymphoma, transformed follicular lymphoma and high grade B-cell lymphoma, acute lymphoblastic leukemia / B-cell Non-Hodgkin lymphoma, Non-Hodgkin lymphoma, mantle cell lymphoma, acute myeloid leukemia, generalized myasthenia gravis (MG), renal transplantation (HLA-A2), gastric adenocarcinoma, ovarian / endometrial cancer, chronic lymphocytic leukemia, follicular lymphoma, renal cell carcinoma, melanoma, basal cell carcinoma, lung cancer, sarcoma, head and neck cancer, cervical cancer, neuro gastro-intestinal (GI) Cancer, breast cancer, hepatocellular carcinoma, nasopharyngeal carcinoma and ovarian cancer.
Currently, therapies targeting melanoma capture 96% of the overall TCR therapies market share. This can be attributed to the fact that melanoma is the most common type of skin cancer for which various TCR therapies are being evaluated in clinical trials. Further, the food and drug administration has approved a TCR therapy (Kimmtrak) for the treatment of advanced uveal melanoma, reinforcing the significance of T-cell therapy in this segment, which is anticipated to elevate the demand for T-cell therapies. In the coming years, TCR therapies targeting hepatocellular carcinoma are expected to grow at an annualized growth rate of 43%.
Based on the type of target antigens, the T-cell therapy market is segmented into BCMA, CD19, CD20, CD19 and CD22, HLA, MAGE, PRAME, NY-ESO-1 and LAGE, EBV, HBV and Others. Currently, CAR-T therapies targeting CD19 antigen capture 66% of the overall CAR-T therapies market share. This can be attributed to the fact that CD19 is an essential antigen for CAR T-cell treatments targeting B-cell malignancies, such as leukemia and lymphoma. In addition, remarkable efficacy of CD19-targeted therapies in the treatment of various types of cancers make it an attractive target antigen for cancer immunotherapy, fostering the demand for T-cell therapies over the forecast period.
Based on the geographical regions, the T-cell therapy market is segmented across North America, Europe, and Asia-Pacific, Latin America, Middle East and North Africa, and rest of the world. According to our projections, currently, North America captures 73% of the overall TCR therapy market. The region is likely to hold the leading position in the market for TCR therapies owing to its robust research and commercial manufacturing foundation, expansive end-use industry, and a growing number of clinical trials.
However, the market for TCR therapies in Asia-Pacific is expected to grow at a relatively faster pace (CAGR of more than 45%), till 2035. This trend has been validated through qualitative insights provided by various industry experts during primary research, which attest to the fact that cell therapy industry in China has witnessed growing interest from investment firms in past few years. The drug developers and research / academic institutes based in China utilize the raised capital to procure vast medical resources and fast-track clinical research for T-cell therapies. Furthermore, the rising incidence of various types of cancers, such as hematologic malignancies and solid tumors, and a surge in demand for curative cancer therapeutics is expected to drive the growth of the market in this region.
For the purpose of this report, sales / revenue data for 2023 is presented for the below mentioned therapies. Kindly note that the list (mentioned below) highlights all the FDA approved T-cell therapies (till August 2024) and has been arranged in the chronological order of their approval year:
CAR-T Therapies:
TCR Therapies:
TIL Therapies:
It is worth noting that since their first approval, a number of these drugs have received indication expansions.
The “T-Cell Therapy Market (7th Edition): Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape, market size, market forecast and future opportunities for the companies involved in development of T-Cell therapies. Key takeaways of the market report are briefly discussed below.
An in-depth analysis of the pipeline shows that close to 15 T cell therapies (CAR-T, TCR and TIL) have been commercialized for targeting various cancer indications. This is followed by more than 1,040 T-cell therapy programs which are in clinical phases of development. Additionally, it is worth mentioning that close to 25% of therapies targeting oncological disorders are in the early (pre-clinical and discovery phase) stages of development. At present, of the approved CAR T cell therapies, six have been approved for several hematological malignancies in the US; these are Tisagenlecleucel-T (KYMRIAH®), Axicabtagene ciloleucel (YESCARTA®), Brexucabtagene Autoleucel (TECARTUS™), Lisocabtagene maraleucel (Breyanzi®), Idecabtagene Vicleucel (Abecma™) and Ciltacabtagene Autoleucel (CARVYKTI™). The currently approved candidates target the CD19 receptor and BCMA.
Further, only two TCR therapies have been approved till date; these are Kimmtrak and Tecelra, for the treatment of melanoma and sarcoma, respectively. Interestingly, in February 2024, the US Food and Drug Administration also approved the first TIL therapy, named Amtagvi (lifileucel), for the treatment of melanoma.
The T-cell market features the presence of over 270 therapy developers. Further, the market is characterized by the presence of mid-sized players (37%), followed by small (36%) and large players (27%). It is worth mentioning that more than 43% of the players are headquartered in Asia-Pacific. In addition, in order to gain a competitive edge and capture the majority of the market share with the expanding geographical reach, big pharma players in this domain are focusing on heavy investment in R&D, manufacturing capabilities, and strategic partnerships. For instance, in February 2024, BioNTech and Autolus declared a strategic CAR-T cell therapy collaboration to advance the pipeline and expand late-stage programs.
With the emergence of innovation and technological advancements, the T-cell therapy market is evolving rapidly, and the market dynamics are changing. The existing established pharmaceutical companies, biotechnology firms, and emerging startups are boosting the competitive landscape by initiating and commercializing innovative T-cell therapies for various types of cancer.
The T-cell therapy industry is experiencing a transformative period, marked by innovation and technological advancements. One of the most notable trends in the T-cell therapy market is the focus on developing innovative therapies that utilize the power of the immune system to combat cancer. Distinguished pharmaceutical and biotechnology firms are adopting this approach to develop innovative therapies that harness the body's natural protection, particularly T cells, to target and destroy cancer cells.
These advanced therapies offer a promising approach, enhance the immune system's ability to recognize and attack tumors and provide more effective and targeted cancer treatment. For instance, in August 2023, the FDA granted orphan drug designation to NXC-201 for treating patients with multiple myeloma. NXC-201 is a next-generation BCMA targeting chimeric antigen receptor (CAR) T-cell therapy. The drug was developed to offer a different mechanism than FDA approved CAR T-cell agents such as tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta).
The global market for CAR-T cell therapies market segment is anticipated to reach USD 15.25 billion by 2035, growing at a CAGR of 11% during the forecast period. A large number of regulatory approvals by the European Medicines Agency (EMA), engagement of research institutions & medical centers in developing CAR-T cell therapies, and escalating investment by pharma and biotech companies for the development of new cell therapies, are some of the key factors anticipated to accelerate the growth of the market in the European region over this forecast period.
Additionally, the market for CAR-T therapies in the Asia-Pacific region is anticipated to expand with 21% CAGR over the forecast period, with several key driving factors, such as increasing interest of stakeholders and investment in T-cell therapies, rising R&D and T-cell immunotherapy clinical trials, surge in patient population, and augmenting collaboration and partnerships between domestic and global companies in the region.
The trend of next-generation CAR T-cell therapies in the T-cell market is representing a significant advancement in the field of cancer treatment, specifically, immunotherapy. Researchers are emphasizing on the development of CAR T-cell therapies with enhanced efficacy and safety to address existing challenges and improve patient outcomes. This next-generation CAR-T therapies are being developed to target multiple antigens. These multiple or dual-targeting CAR T cells aid in controlling the risk of tumor recurrence.
Besides this, allogeneic cell therapy are also gaining traction in the T-cell therapy market as they are sourced from healthy donor cells instead of patients' own which makes it a more attractive option for their potential scalability and off-shelf availability.
Examples of key companies engaged in the T-cell therapy industry (which have also been profiled in this market report; the complete list of companies is available in the full report) include Adaptimmune Therapeutics, Alaunos Therapeutics, Autolus, bluebird Bio, Bristol Myers Squibb, Carsgen Therapeutics, Cellectis, Cellular Biomedicine Group, Gilead Sciences, and GlaxoSmithKline. This market report includes an easily searchable excel database of all the T-cell therapy companies.
The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders in this industry, across different geographies. Amongst other elements, the market report includes:
In the past few years, the market for T-cell therapy has been blooming. Several ongoing innovations and developments are projected to boost market potential. These developments, even if they took place post the release of our market report, substantiate the overall trends that have been outlined in our market analysis.